Related Stories Semaglutide outperforms other GLP-1 drugs for weight loss in psychiatric populations Trial successfully lowers alcohol use in humanitarian setting Newer GLP-1 medications may reduce alcohol-related hospitalization risk The outpatient segment involved nine weeks of treatment with either semaglutide or placebo and the effect of the treatments were evaluated in the 10th week
Why women need lower doses Biological differences: Smaller average body size Different hormone profiles More sensitive to some peptides Better response at lower doses often General rule: Start 20-30% lower than male doses Women: 150-200mcg vs Men: 200-300mcg (GH peptides) Titrate based on response More isn't better for women Hormone cycle considerations (perimenopause) If still menstruating: GH peptides: Use consistently throughout cycle Weight loss peptides: May work better in follicular phase (days 1-14) Some women dose higher during luteal phase (more resistant) Track response across full cycle Post-menopause: No cycle to consider Consistent dosing easier More predictable results Age-specific dosing Women 40-50 (perimenopause): Start conservative Body still producing some hormones Lower doses effective Women 50-60 (menopause): Standard doses appropriate Need more GH replacement Can titrate higher if needed Women 60-70+: Start very low Increase slowly More sensitive to side effects Benefits still significant Safety considerations for women over 40 Special precautions for this demographic
Studies demonstrate Epithalon's ability to influence gene expression and protein synthesis during neurogenesis
Semaglutide enhances and prolongs these effects, leading to several key benefits: Appetite Regulation and Satiety: Semaglutide acts on the brains appetite centers, reducing hunger signals and increasing feelings of fullness
I feel great #glp1 #glp1life #myglp1journey lets talk side effects
Manufacturing deficiencies: Some pharmacies received warning letters for manufacturing practices that did not meet applicable standards, including inadequate sterility assurance, deficient testing, and improper facility conditions
